Literature DB >> 20920695

Adherence to oral contraception in women on Category X medications.

Amy Steinkellner1, William Chen, Shannon E Denison.   

Abstract

BACKGROUND: Over 6% of women become pregnant when taking teratogenic medications, and contraceptive counseling appears to occur at suboptimal rates. Adherence to contraception is an important component in preventing unwanted pregnancy and has not been evaluated in this population. We undertook a pharmacy claims-based analysis to evaluate the degree to which women of childbearing age who receive Category X medications adhere to their oral contraception.
METHODS: We evaluated the prescription medication claims for over 6 million women, age 18-44 years, with prescription benefits administered by a pharmacy benefits manager. Women with 2 or more claims for a Category X medication and 2 or more claims for oral contraception were evaluated in further detail. Adherence to oral contraception was measured by analyzing pharmacy claims. Multivariable logistic regression was performed to identify factors associated with adherence.
RESULTS: There were 146,758 women of childbearing age who received Category X medications, of which 26,136 also took oral contraceptive medication. Women who received Category X medications were prescribed oral contraception (18%) at rates similar to others of childbearing age (17%). Women prescribed both Category X and oral contraception demonstrated adherence similar to the overall population. Age, class of Category X medication, number of medications, prescriber's specialty, and ethnicity correlated with lower adherence rates.
CONCLUSIONS: Despite added risk associated with unintended pregnancy, many women who receive Category X medications have refill patterns suggesting nonadherence to oral contraception. Compared with all women age 18-44 years, women receiving teratogenic medications do not have better adherence to oral contraception.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20920695     DOI: 10.1016/j.amjmed.2010.05.009

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  9 in total

1.  Reproductive health and endocrine disruption in women with breast cancer: a pilot study.

Authors:  Ashlesha Patel; Alicia Roston; Almae Uy; Erika Radeke; Arden Roston; Louis Keith; H A Zaren
Journal:  Support Care Cancer       Date:  2014-08-15       Impact factor: 3.603

2.  Using the electronic medical record to refer women taking category D or X medications for teratogen and contraceptive counseling.

Authors:  Sheila K Mody; Jennifer Wu; Marla Ornelas; Colleen Kernahan; Elizabeth Salas; Kelly Kao; Robert Felix; Christina Chambers
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2015-06-23

3.  Effect of arteether and pyrimethamine coadministration on the pharmacokinetic and pharmacodynamic profile of ormeloxifene.

Authors:  Abhisheak Sharma; Swati Jaiswal; Mahendra Shukla; Jawahar Lal
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2017-07-08       Impact factor: 3.000

Review 4.  Statin Adherence: Does Gender Matter?

Authors:  Karen M Goldstein; Leah L Zullig; Lori A Bastian; Hayden B Bosworth
Journal:  Curr Atheroscler Rep       Date:  2016-11       Impact factor: 5.113

5.  Using the electronic medical record to assess contraception usage among women taking category D or X medications.

Authors:  Sheila K Mody; John Paul Farala; Jennifer Wu; Robert Felix; Christina Chambers
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2015-08-25

6.  Contraceptive methods and informed consent among women receiving medications with potential for adverse fetal effects: a Washington, Wyoming, Alaska, Montana, Idaho (WWAMI) region study.

Authors:  Rex W Force; Gina A Keppel; Janelle Guirguis-Blake; Debra A Gould; Chris Vincent; Kavitha Chunchu; Robert M Monger; John T Holmes; Jacintha Cauffield; Laura-Mae Baldwin
Journal:  J Am Board Fam Med       Date:  2012 Sep-Oct       Impact factor: 2.657

7.  Assessment of medication adherence and responsible use of isotretinoin and contraception through Belgian community pharmacies by using pharmacy refill data.

Authors:  Natacha Biset; Mélanie Lelubre; Christelle Senterre; Karim Amighi; Olivier Bugnon; Marie P Schneider; Carine De Vriese
Journal:  Patient Prefer Adherence       Date:  2018-01-19       Impact factor: 2.711

8.  Relationship between self-efficacy and patient knowledge on adherence to oral contraceptives using the Morisky Medication Adherence Scale (MMAS-8).

Authors:  Daniel Tomaszewski; Benjamin D Aronson; Margarette Kading; Donald Morisky
Journal:  Reprod Health       Date:  2017-09-06       Impact factor: 3.223

9.  Effectiveness of Risk Evaluation and Mitigation Strategies (REMS) for Lenalidomide and Thalidomide: Patient Comprehension and Knowledge Retention.

Authors:  Nancy A Brandenburg; Robert Bwire; John Freeman; Florence Houn; Paul Sheehan; Jerome B Zeldis
Journal:  Drug Saf       Date:  2017-04       Impact factor: 5.606

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.